Drugs / GC001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06660056 | Oct 2024 → Feb 2026 overdue | malignant glioma | GONGCHU Biotechnology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06508307 | Apr 2023 → Jan 2026 overdue | breast cancer, cervical cancer, colon carcinoma, gastric cancer +5 | GONGCHU Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06508307 ↗ |
| Modality | Other / unclassified | “GC001 oncolytic virus injection” NCT06508307 ↗ |
| Route | Other | “Intratumoral Injection” NCT06508307 ↗ |